XML 48 R38.htm IDEA: XBRL DOCUMENT
v3.23.1

Collaboration Agreement - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions |  | 1 Months Ended | 3 Months Ended
--- | --- | --- | ---
Jan. 26, 2023 | Jan. 31, 2023 | Dec. 31, 2022 | Mar. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Receivable from collaboration partner |  |  |  | $ 1.2
Kite Collaboration Agreement |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Upfront payment |  | $ 225.0 |  |
Shares purchased price per share | $ 4.39 |  |  |
Estimated transaction price |  |  | $ 198.1 |
Fixed transaction price |  |  | 221.0 |
Variable consideration |  |  | 22.8 |
Reduction of deemed discount on shares sold | $ 15.3 |  | $ 15.3 |
Kite Collaboration Agreement | Maximum |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Percentage of reimbursement costs |  |  |  | 0.00%
Kite Collaboration Agreement | Minimum |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Percentage of reimbursement costs |  |  |  | 0.00%
Kite Collaboration Agreement | United States |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Percentage of out-of-pocket development costs for co-promote products |  |  |  | 40.00%
Kite Collaboration Agreement | Kite Pharma, Inc. | Outside United States |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Percentage of out-of-pocket development costs for co-promote products |  |  |  | 60.00%
Kite Collaboration Agreement | CART-ddBCMA [Member] | Maximum |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Potential payments of clinical, regulatory and commercial milestones |  | 335.0 |  |
Kite Collaboration Agreement | Next Generation Autologous CAR-T Cell Therapy Product | Maximum |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Potential payments of clinical, regulatory and commercial milestones |  | 635.0 |  |
Kite Collaboration Agreement | Non-autologous CAR-T Cell Therapy Product | Maximum |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Potential payments of clinical, regulatory and commercial milestones |  | $ 507.5 |  |
Stock Purchase Agreement and Standstill Agreement |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Standstill restrictions, expiration by month |  |  |  | 18 months
Gilead Common Stock Purchase Agreement |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Shares purchased |  | 3,478,261 |  |
Shares purchased price per share |  | $ 28.75 |  |
Discount on sale of common stock |  | $ 15.3 |  |
Gilead Common Stock Purchase Agreement | Gilead |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Equity investment |  | $ 100.0 |  |

X
- Definition Collaboration agreement, deemed discount on shares sold. + References No definition available. + Details
Name: | aclx_CollaborationAgreementDeemedDiscountOnSharesSold
Namespace Prefix: | aclx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaboration agreement estimated transaction price. + References No definition available. + Details
Name: | aclx_CollaborationAgreementEstimatedTransactionPrice
Namespace Prefix: | aclx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration agreement, fixed transaction price. + References No definition available. + Details
Name: | aclx_CollaborationAgreementFixedTransactionPrice
Namespace Prefix: | aclx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration agreement, upfront payment. + References No definition available. + Details
Name: | aclx_CollaborationAgreementUpfrontPayment
Namespace Prefix: | aclx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaboration agreement variable consideration. + References No definition available. + Details
Name: | aclx_CollaborationAgreementVariableConsideration
Namespace Prefix: | aclx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of out-of-pocket development costs for co-promote products. + References No definition available. + Details
Name: | aclx_PercentageOfOutOfPocketDevelopmentCostsForCoPromoteProducts
Namespace Prefix: | aclx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of reimbursement costs. + References No definition available. + Details
Name: | aclx_PercentageOfReimbursementCosts
Namespace Prefix: | aclx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition potential payments of clinical, regulatory and commercial milestones. + References No definition available. + Details
Name: | aclx_PotentialPaymentsOfClinicalRegulatoryAndCommercialMilestones
Namespace Prefix: | aclx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Standstill restrictions, expiration by month. + References No definition available. + Details
Name: | aclx_StandstillRestrictionsExpirationByMonth
Namespace Prefix: | aclx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 954 -SubTopic 310 -Section 45 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=126942793&loc=d3e3073-115593 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(5)) -URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910 + Details
Name: | us-gaap_AccountsReceivableNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Discount on common shares, or any unamortized balance thereof, shown separately as a deduction from the applicable account(s) as circumstances require. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.4-07) -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187103-122770 + Details
Name: | us-gaap_CommonStockDiscountOnShares
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 45 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(10)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599 + Details
Name: | us-gaap_EquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644 + Details
Name: | us-gaap_SharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Per share or per unit amount of equity securities issued. + References No definition available. + Details
Name: | us-gaap_SharesIssuedPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=aclx_KiteCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=aclx_KitePharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=aclx_CartDdbcmaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=aclx_NextGenerationAutologousCarTCellTherapyProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=aclx_NonAutologousCarTCellTherapyProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=aclx_StockPurchaseAgreementAndStandstillAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=aclx_GileadCommonStockPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=aclx_GileadMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |